EUCTR2019-003008-11-BE进行中（未招募）1 期
An Open-Label, Single Ascending Dose Study to Evaluate the Pharmacokinetics and Safety of Solriamfetol in Pediatric Subjects with Narcolepsy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female subjects 6 to < 18 years old at Screening, depending on Group.
- •2. Minimum body weight of 22 kg.
- •3. Subjects with diagnosis of narcolepsy according to International Classification of Sleep Disorders-3 (ICSD-3) criteria, or, with the permission of the medical monitor, completed a Multiple Sleep Latency Test during Screening to confirm the diagnosis of narcolepsy by ICSD-3 criteria (ie, the subject met all other ICSD-3 criteria for narcolepsy). 4. Subjects with documented written assent per Institutional Review Board (IRB) / Ethics Committee (EC) requirements indicating that he/she is aware of the investigational nature of the study and the required procedures and restrictions before participation in any protocol-related activities.
- •5. Parent(s)/guardian(s) must give their written informed consent for his/her/their child’s participation in the study.
- •6. Female subjects of childbearing potential (ie, fertile, following menarche) and male subjects who have female partners of childbearing potential must agree to use, at a minimum, medically acceptable methods of contraception with their partners from Screening, throughout the study, and for 30 days after the last dose of solriamfetol. Medically acceptable methods of contraception that may be used by the subject include abstinence (when this is in line with the preferred and usual lifestyle of the subject), progestogenonly oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, and a combination of a male condom with either cap, diaphragm, or sponge with spermicide (double barrier methods). For greater protection, subjects may optionally use highly effective contraceptive methods. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, single barrier methods (male or female condom with or without spermicide; cap, diaphragm, or sponge with spermicide), and lactational amenorrhoea method are not acceptable methods of contraception for this study. Female condom and male condom should not be used together.
- •7. Subjects must agree to abstain from alcohol and nicotine-containing products; including tobacco (eg, cigarettes, cigars, chewing tobacco, snuff), e-cigarettes, and nicotine lozenge/gum/patch within 3 days prior to each dosing in Periods 1, 2, and 3 through discharge from that period. Subjects must also agree to abstain from consuming caffeine on the day prior to dosing (Day -1) and the day of dosing (Day 1) in Periods 1, 2, and 3.
- •8. Subjects must agree to discontinue use of over-the-counter or prescription stimulants (eg, pseudoephedrine, methylphenidate, amphetamines, modafinil, armodafinil, and pitolisant) the day before dosing and on each day when receiving a dose of solriamfetol.
- •9. Subjects must have sufficient blood volume for PK sampling based on body weight in accordance with applicable guidance (eg, European Commission’s recommendations document Ethical considerations for clinical trials on medicinal products conducted with minors” 2017, or according to the IRB/EC guidelines).
- •10. Subjects must be willing and able to comply with the study schedule, all study procedures, and other requirements.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 12
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Subjects with any significant abnormality in the physical or psychological finding, or clinical laboratory results that could interfere with the study conduct or the ability of the subject to complete the study based on the judgement of the investigator, or place the subject at risk during the trial or compromise the study objectives.
- •2. Subjects with history of increased ocular pressure or at risk of angle closure glaucoma, or with clinically significant disorders other than narcolepsy, including but not limited to, endocrine, neoplastic, gastrointestinal, hematological, hepatic, immunologic, metabolic, neurological (other than narcolepsy/cataplexy), pulmonary, renal disease, behavioral, or psychiatric disorder, which could interfere with the study conduct or the ability of the subject to complete the study based on the judgement of the investigator, or place the subject at risk during the study or compromise the study objectives.
- •3. Subjects with uncontrolled hypertension, uncontrolled cardiac arrhythmias, or systolic blood pressure and/or diastolic blood pressure values > the 95th percentile for sex, age, and height, any clinically significant electrocardiogram (ECG) abnormality in the opinion of the Investigator, or any history of cardiovascular disease or any significant cardiovascular condition that in the Investigator’s opinion may jeopardize a subject’s safety in the study.
- •4. Subjects with an estimated creatinine clearance (CrCL) < 90 mL/min.
- •5. Female subjects who are pregnant, nursing, or lactating.
- •6. Subjects with self-reported consumption of more than 200 mg of caffeine per day (for example, more than 12 oz [approximately 355 mL] of coffee).
- •7. Subjects with hemoglobin < normal range for age and gender at Screening.
- •8. Subjects who are positive for urine drug screening for opiates, barbiturates, amphetamine, tetrahydrocannabinol (THC), benzodiazepines, or cocaine unless the subject is receiving prescribed drugs.
- •9. Subjects who are positive for the alcohol breath test.
- •10. Subjects who donated blood within 1 month before the start of the study.
- •11. Subjects who received any investigational drug within 30 days or 5 half-lives (whichever is longer) before Screening.
- •12. Subjects who are receiving monoamine oxidase inhibitors (MAIOs), or who might receive MAOIs within 14 days prior to the first dose of solriamfetol.
- •13. Subjects with allergy to any components of topical, local anesthetics that might be used for blood collection (not applicable if numbing agents will not be used).
- •14. Subjects with history or presence of phenylketonuria or hypersensitivity or idiosyncratic reaction to phenylalanine-derived products, or any excipient in the formulated drug products.
- •15. Subjects with current suicidal risk as determined from history, or Columbia-Suicide Severity Rating Scale (C-SSRS), or history of suicide attempt.
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate the safety of solriamfetol, and the way the body handles it, in children with narcolepsyarcolepsyMedDRA version: 21.1Level: LLTClassification code 10021235Term: Idiopathic narcolepsySystem Organ Class: 100000004852EUCTR2019-003008-11-ITJAZZ PHARMACEUTICALS INC12
已完成
1 期
A study to evaluate the safety, tolerability, pharmacokinetics (PK – how your body uses the study drug) and pharmacodynamics (PD – how the study drug carries out its actions on the body) profile of Inclacumab following a single intravenous infusion in healthy participantsBlood - Haematological diseasesHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersSickle Cell DiseaseACTRN12620001156976inear Clinical Research Ltd15
进行中（未招募）
1 期
open - label trial with ascending dose to evaluate safety, tolerability and efficacy of EDIT-101 in adult and children with Leber Congenital Amaurosis Type 10 (LCA10)EUCTR2019-004981-16-NLEditas Medicine, Inc.18
撤回
2 期
Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants with Leber Congenital Amaurosis Type 10 (LCA10), with Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in Intron 26 (IVS26) of the CEP290 Gene (*LCA10-IVS26*)CEP290-gene mutation and inherited retinal degeneration10015920NL-OMON54872Editas Medicine, Inc.2
已完成
不适用
An open-label, single ascending dose study to evaluate the safety and pharmacokinetics of a tablet formulation of CG-549 in healthy subjectsbacterial infections10004018NL-OMON48209CrystalGenomics, Inc24